S&P 500   5,248.49
DOW   39,760.08
QQQ   444.83
Stock market today: World shares are mostly higher after S&P 500 sets another record
The Most Bought AI Stock by Congress Isn’t NVIDIA
5 Dividend Kings Stocks to Load Up on Now
Chinese leader Xi issues a positive message at a meeting with US business leaders as ties improve
Palantir Technologies: Bearish Sentiment, Bullish Chart Signals
Mid-Cap Stocks to Outperform the Market This Cycle
Is DraftKings A Good Bet Ahead of Q1 Earnings?
S&P 500   5,248.49
DOW   39,760.08
QQQ   444.83
Stock market today: World shares are mostly higher after S&P 500 sets another record
The Most Bought AI Stock by Congress Isn’t NVIDIA
5 Dividend Kings Stocks to Load Up on Now
Chinese leader Xi issues a positive message at a meeting with US business leaders as ties improve
Palantir Technologies: Bearish Sentiment, Bullish Chart Signals
Mid-Cap Stocks to Outperform the Market This Cycle
Is DraftKings A Good Bet Ahead of Q1 Earnings?
S&P 500   5,248.49
DOW   39,760.08
QQQ   444.83
Stock market today: World shares are mostly higher after S&P 500 sets another record
The Most Bought AI Stock by Congress Isn’t NVIDIA
5 Dividend Kings Stocks to Load Up on Now
Chinese leader Xi issues a positive message at a meeting with US business leaders as ties improve
Palantir Technologies: Bearish Sentiment, Bullish Chart Signals
Mid-Cap Stocks to Outperform the Market This Cycle
Is DraftKings A Good Bet Ahead of Q1 Earnings?
S&P 500   5,248.49
DOW   39,760.08
QQQ   444.83
Stock market today: World shares are mostly higher after S&P 500 sets another record
The Most Bought AI Stock by Congress Isn’t NVIDIA
5 Dividend Kings Stocks to Load Up on Now
Chinese leader Xi issues a positive message at a meeting with US business leaders as ties improve
Palantir Technologies: Bearish Sentiment, Bullish Chart Signals
Mid-Cap Stocks to Outperform the Market This Cycle
Is DraftKings A Good Bet Ahead of Q1 Earnings?
LON:DOCS

Dr. Martens (DOCS) Share Price, News & Analysis

GBX 88.90
+0.10 (+0.11%)
(As of 05:42 AM ET)
Today's Range
85.75
90.45
50-Day Range
73.75
97.80
52-Week Range
72.25
174.70
Volume
32,124 shs
Average Volume
1.14 million shs
Market Capitalization
£855.08 million
P/E Ratio
889.00
Dividend Yield
6.75%
Price Target
GBX 177.50

Dr. Martens MarketRank™ Stock Analysis

Analyst Rating
Moderate Buy
2.50 Rating Score
Upside/​Downside
99.7% Upside
GBX 177.50 Price Target
Short Interest
N/A
Dividend Strength
Weak
Based on Four Factors
Sustainability
N/A
News Sentiment
0.67mentions of Dr. Martens in the last 14 days
Based on 4 Articles This Week
Insider Trading
Acquiring Shares
£44,945 Bought Last Quarter
Proj. Earnings Growth
N/A

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

2.72 out of 5 stars

DOCS stock logo

About Dr. Martens Stock (LON:DOCS)

Dr. Martens plc designs, develops, procures, markets, sells, and distributes footwear in Europe, the Middle East, Africa, the Americas, and the Asia-Pacific. It offers originals, fusion, kids, and casual, as well as accessories. The company offers its products under the Dr. Martens brand name. Dr. Martens plc was founded in 1945 and is based in London, the United Kingdom.

DOCS Stock Price History

DOCS Stock News Headlines

The Small Biotech with a BIG Cancer Solution
There's a new cancer treatment so precise, it's been called a "smart bomb." One that can deliver a toxic payload directly to tumors while bypassing healthy cells.
The Small Biotech with a BIG Cancer Solution
There's a new cancer treatment so precise, it's been called a "smart bomb." One that can deliver a toxic payload directly to tumors while bypassing healthy cells.
What on earth is going on with this FTSE 250 stock?
See More Headlines
Receive DOCS Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Dr. Martens and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Ex-Dividend for 2/2 Dividend
1/04/2024
Dividend Payable
2/02/2024
Today
3/27/2024

Industry, Sector and Symbol

Industry
Footwear & Accessories
Sub-Industry
N/A
CIK
N/A
Fax
N/A
Employees
2,591
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
GBX 177.50
High Stock Price Target
GBX 180
Low Stock Price Target
GBX 175
Potential Upside/Downside
+99.9%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.50
Research Coverage
2 Analysts

Profitability

Net Income
£103.20 million
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
£977.50 million
Cash Flow
GBX 6.22 per share
Book Value
GBX 37 per share

Miscellaneous

Free Float
N/A
Market Cap
£854.12 million
Optionable
Not Optionable
Beta
-0.02
5G Stocks: The Path Forward is Profitable Cover

Click the link below and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise.

Get This Free Report

Key Executives

  • Mr. Kenneth Wilson (Age 58)
    CEO & Director
    Comp: $773k
  • Mr. Jon William Mortimore (Age 57)
    CFO & Director
    Comp: $503k
  • Mr. Onyeije Ogueri Nwokorie (Age 54)
    Chief Brand Officer
    Comp: $67k
  • Mr. Geert Peeters (Age 58)
    Chief Operating Officer
  • Mr. Ronald Garricks
    Chief Information Officer
  • Ms. Meg Johnson
    Chief Marketing Officer
  • Ms. Emily Clare Reichwald (Age 49)
    Chief People & Sustainability Officer and Company Secretary
  • Mr. Sean O'Neill
    Chief Digital Officer
  • Mr. Derek Chan
    President of APAC
  • Mr. Adam M. Meek
    Chief Product Officer

DOCS Stock Analysis - Frequently Asked Questions

Should I buy or sell Dr. Martens stock right now?

2 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Dr. Martens in the last year. There are currently 1 hold rating and 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" DOCS shares.
View DOCS analyst ratings
or view top-rated stocks.

What is Dr. Martens' stock price target for 2024?

2 equities research analysts have issued twelve-month price objectives for Dr. Martens' shares. Their DOCS share price targets range from GBX 175 to GBX 180. On average, they anticipate the company's stock price to reach GBX 177.50 in the next twelve months. This suggests a possible upside of 99.7% from the stock's current price.
View analysts price targets for DOCS
or view top-rated stocks among Wall Street analysts.

How have DOCS shares performed in 2024?

Dr. Martens' stock was trading at GBX 88.60 at the beginning of the year. Since then, DOCS stock has increased by 0.3% and is now trading at GBX 88.90.
View the best growth stocks for 2024 here
.

How often does Dr. Martens pay dividends? What is the dividend yield for Dr. Martens?

Dr. Martens announced a dividend on Saturday, November 30th. Stockholders of record on Thursday, January 4th will be paid a dividend of GBX 1.56 per share on Friday, February 2nd. This represents a yield of 1.36%. The ex-dividend date of this dividend is Thursday, January 4th. The official announcement can be seen at this link.
Read our dividend analysis for DOCS
.

Is Dr. Martens a good dividend stock?

Dr. Martens (LON:DOCS) pays an annual dividend of GBX 6 per share and currently has a dividend yield of 6.71%. DOCS has a dividend yield higher than 75% of all dividend-paying stocks, making it a leading dividend payer. The dividend payout ratio is 6,000.00%. Payout ratios above 75% are not desirable because they may not be sustainable.
Read our dividend analysis for DOCS.

How do I buy shares of Dr. Martens?

Shares of DOCS stock and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock.
Compare Top Brokerages Here.

This page (LON:DOCS) was last updated on 3/28/2024 by MarketBeat.com Staff

From Our Partners